FDA approves giredestrant with everolimus for ESR1-mutated advanced or metastatic breast cancer
FDA has approved giredestrant (Wilserdly) with everolimus for ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer; the trial's PFS hazard ratio was 0.38. Adults whose disease progressed on endocrine therapy now have an approved combination and an authorized ESR1 test.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
Adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer now have an approved regimen that pairs the oral estrogen receptor antagonist giredestrant with everolimus, after a progression-free survival hazard ratio of 0.38 against physician's choice of endocrine therapy among the 207 patients with ESR1-mutated tumors in the 373-participant evERA Breast Cancer trial, the FDA said. The agency approved giredestrant (Wilserdly, Genentech, Inc.) for adults whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting. In the same action, FDA authorized the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for the combination, the agency said.
| Arm | Endocrine therapy | Median PFS | Objective response rate |
|---|---|---|---|
| Giredestrant and everolimus | Giredestrant 30 mg once daily | 10 months (95% CI: 8.1, 12.9) | 27% (95% CI: 18, 37) |
| Physician's choice and everolimus | Physician's choice of endocrine therapy | 5.5 months (95% CI: 3.8, 5.6) | 14% (95% CI: 8, 22) |
Giredestrant and everolimus
-
- Endocrine therapy
- Giredestrant 30 mg once daily
- Median PFS
- 10 months (95% CI: 8.1, 12.9)
- Objective response rate
- 27% (95% CI: 18, 37)
Physician's choice and everolimus
-
- Endocrine therapy
- Physician's choice of endocrine therapy
- Median PFS
- 5.5 months (95% CI: 3.8, 5.6)
- Objective response rate
- 14% (95% CI: 8, 22)
From the FDA's November 16, 2026 announcement on the evERA Breast Cancer trial (NCT05306340).
Why it matters
Giredestrant is an oral estrogen receptor antagonist, the FDA said. The comparator in the trial was physician's choice of endocrine therapy, which included exemestane, fulvestrant, or tamoxifen, and patients in both arms received everolimus 10 mg once daily. FDA also authorized the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with giredestrant in combination with everolimus, the agency said. The review was conducted under Project Orbis in collaboration with Health Canada and Israel's Ministry of Health, and FDA approved the application 4 weeks ahead of the FDA goal date.
Approval date and dose
On November 16, 2026, FDA approved giredestrant (Wilserdly, Genentech, Inc.) in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting. The recommended dose is giredestrant 30 mg taken orally once daily with or without food until disease progression or unacceptable toxicity; everolimus dosing follows that drug's own prescribing information.
The evERA Breast Cancer trial
Efficacy was evaluated in evERA Breast Cancer (NCT05306340), a randomized, open-label, multicenter trial in 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 patients whose tumors had ESR1 mutations, the FDA said. Patients were randomized 1:1 to receive giredestrant 30 mg once daily (N=183) or physician's choice of endocrine therapy (N=190). Patients in both arms also received everolimus 10 mg once daily and were treated until disease progression or unacceptable toxicity. Pre- and peri-menopausal female patients received a GnRH agonist for ovarian function suppression; male patients also received a GnRH agonist, except in the case of bilateral orchiectomy.
The primary efficacy outcome measure was progression-free survival by investigator assessment per RECIST version 1.1. The trial demonstrated a statistically significant improvement in progression-free survival for giredestrant and everolimus compared with physician's choice of endocrine therapy and everolimus in patients whose tumors had ESR1 mutations, the FDA said.
- Progression-free survival hazard ratio in the ESR1-mutated population: 0.38 (95% CI: 0.27, 0.54; p<0.0001)
- Median PFS: 10 months (95% CI: 8.1, 12.9) in the giredestrant and everolimus arm and 5.5 months (95% CI: 3.8, 5.6) in the physician's choice and everolimus arm
- Objective response rate: 27% (95% CI: 18, 37) and 14% (95% CI: 8, 22) in the respective arms
Circulating tumor DNA was assessed centrally to determine ESR1 mutational status using the FoundationOne Liquid CDx assay, limited to specific ESR1 mutations in the ligand binding domain, the FDA said.
Safety
The most common adverse reactions (≥20%) in patients receiving giredestrant plus everolimus were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea, the FDA said. The most common laboratory abnormalities were decreased hemoglobin, decreased lymphocytes, decreased WBC count, increased AST, increased ALT, decreased neutrophils, decreased platelets, decreased calcium, decreased potassium, increased creatinine, and decreased sodium. The prescribing information includes warnings and precautions for bradycardia and embryo-fetal toxicity.
What remains uncertain
Overall survival data were immature at the time of the progression-free survival analysis, the FDA said.